Variations in radioiodine ablation: decision-making after total thyroidectomy
- 49 Downloads
The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today.
We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies.
Results and Conclusion
We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.
KeywordsRadioiodine Thyroidectomy Treatment Decision Making
The project was funded by a non-profit grant by Krebsliga Beider Basel as mentioned in the submission portal.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This survey analyses the participating centres for their treatment strategies. This information is derived directly from the clinical experts; individual patient data was not accessed.
- 1.Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefGoogle Scholar
- 9.Hundsberger T, et al. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes—the Pompe disease burden scale. J Neurol. 2019.Google Scholar
- 14.Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993. 114;(6):1050–7.Google Scholar
- 19.Glatzer M, et al. Decision-making criteria in oncology. Oncology. 2018;1–9.Google Scholar
- 21.Steffen T, et al. Diagnostic nodes of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy among colorectal cancer patients: a Swiss National Multicenter Survey. Clin Colorectal Cancer. 2019.Google Scholar
- 28.Tuttle RM, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid Cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461–70.CrossRefGoogle Scholar
- 31.(NCCN), N.C.C.N., Thyroid carcinoma, in Thyroid Carcinoma (Version 2.2018). 2018.Google Scholar